Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction

Clicks: 364
ID: 270971
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 28 articles by views in cardiovascular therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A 24-h infusion with levosimendan transiently improved the renal dysfunction compared with placebo in patients with DHF, and its beneficial effects persisted for at least 14 days after the initiation of treatment.
Reference Key
zq2013cardiovasculareffect Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hou ZQ;Sun ZX;Su CY;Tan H;Zhong X;Hu B;Zhou Y;Shang DY;;
Journal cardiovascular therapeutics
Year 2013
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/23490237
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE China humans pubmed abstract nih national institutes of health national library of medicine treatment outcome female male aged middle aged Prospective Studies 80 and over linear models Randomized Controlled Trial Double-Blind Method chi-square distribution time factors analysis of variance intravenous hospitalization* biomarkers / blood infusions natriuretic peptide brain / blood heart rate / drug effects ventricular function left / drug effects heart failure / complications heart failure / diagnosis heart failure / drug therapy* simendan hydrazones / therapeutic use* pyridazines / therapeutic use* cardiotonic agents / therapeutic use* pmid:23490237 doi:10.1111/1755-5922.12001 zhi-qiang hou zhao-xia sun de-ya shang blood pressure / drug effects cardiotonic agents / administration & dosage glomerular filtration rate / drug effects* heart failure / blood heart failure / physiopathology hydrazones / administration & dosage kidney diseases / blood kidney diseases / complications kidney diseases / physiopathology* pyridazines / administration & dosage stroke volume urination / drug effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.